Program
Roflumilast
Also written as “Roflumilast Cream 0.15%”, “Roflumilast Cream 0.3%” and “ARQ-151 cream 0.05%”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Psoriasis · Dermatitis, Atopic · Asthma · Diabetes Mellitus, Type 2, led by 8 companies.
Drug pageRoflumilast: every studyMany companies study it; this page follows only the 61 they lead. All 118 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 340 open or running | phase 4since Mar 30, 2011 | Jun 9, 2003 | none ahead |
| Arcutis Biotherapeuticsits history only | 181 open or running | phase 3since Dec 23, 2019 | Dec 29, 2017 | Apr 27, 2028phase 3 · NCT07916480 |
| Huadong Medicineits history only | 31 open or running | phase 3since Sep 30, 2024 | Sep 30, 2024 | Jun 30, 2027phase 3 · NCT07683806 |
| FLUIDDA nvits history only | 20 open or running | phase 4since Nov 21, 2011 | Nov 21, 2011 | none ahead |
| Integrative Skin Science and Researchits history only | 11 open or running | phase 4since Apr 23, 2026 | Apr 23, 2026 | Aug 2027phase 4 · NCT07560618 |
| Padagisits history only | 10 open or running | phase 3since Feb 28, 2023 | Feb 28, 2023 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 2since Jan 25, 2016 | Jan 25, 2016 | none ahead |
| Takedaits history only | 10 open or running | phase 1since Mar 4, 2014 | Mar 4, 2014 | none ahead |
Also a collaborator on its studies: Tanabe Pharma, Fougera Pharmaceuticals and Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Jun 9, 2003.
- Jun 8, 2010Phase 2 study in Diabetes Mellitus, Type 2NCT01140542 · 487 enrolled
- Mar 3, 2011Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT01313494 · 626 enrolled · China, Hong Kong, Singapore
- Mar 30, 2011Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT01329029 · 1,945 enrolled · Australia, Austria, Belgium and more
- May 16, 2011Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT01354782 · 32 enrolled · China
- May 30, 2011Phase 2 study in Allergic AsthmaNCT01365533 · 48 enrolled · Canada
- Sep 28, 2011Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT01443845 · 2,354 enrolled · United States, Argentina, Canada and more
- Oct 31, 2011Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT01473758 · 81 enrolled · United Kingdom
- Dec 21, 2011Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT01509677 · 158 enrolled · Denmark, Germany, Poland and more
- Aug 10, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01664624 · 40 enrolled · United States
- Oct 2, 2012Phase 2 study in Nonalcoholic SteatohapatitisNCT01703260 · 20 enrolled · United States
- Jan 8, 2013Phase 2 study in AsthmaNCT01765192 · 64 enrolled · Germany, Hungary, South Africa
- May 14, 2013Phase 2 study in Dermatitis, AtopicNCT01856764 · 40 enrolled · Germany
- Jan 29, 2014Phase 1 study in Memory DisordersNCT02051335 · 27 enrolled · United Kingdom
- May 2, 2014Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT02165826 · 1,323 enrolled · Slovakia
TargetBeta
“An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities”NCIt, by rule
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule
Other programs on the same 5 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ensifentrinerule | Merck | phase 3 | 17 |
Studies
All 34 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02165826Pulmonary Disease, Chronic Obstructive · Slovakia | 3 | Completed | Sep 1, 2015 | 1,323 |
| NCT02051335Memory Disorders · United Kingdom | 1 | Completed | May 2014 | 27 |
| NCT01856764Dermatitis, Atopic · Germany | 2 | Completed | Mar 2014 | 40 |
| NCT01765192Asthma · Germany, Hungary, South Africa | 2 | Completed | Oct 2013 | 64 |
| NCT01703260Nonalcoholic Steatohapatitis · United States | 2 | Terminated | Sep 2014 | 20 |
| NCT01664624Diabetes Mellitus, Type 2 · United States | 1 | Completed | Nov 2012 | 40 |
| NCT01509677Pulmonary Disease, Chronic Obstructive · Denmark, Germany, Poland and more | 3 | Completed | Feb 1, 2016 | 158 |
| NCT01473758Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Terminated | Mar 2014 | 81 |
| NCT01443845Pulmonary Disease, Chronic Obstructive · United States, Argentina, Canada and more | 4 | Completed | Nov 30, 2015 | 2,354 |
| NCT01365533Allergic Asthma · Canada | 2 | Completed | Jul 2005 | 48 |
| NCT01354782Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | Jun 2011 | 32 |
| NCT01329029Pulmonary Disease, Chronic Obstructive · Australia, Austria, Belgium and more | 4 | Completed | Mar 2014 | 1,945 |
| NCT01313494Pulmonary Disease, Chronic Obstructive · China, Hong Kong, Singapore | 3 | Completed | May 2012 | 626 |
| NCT01140542Diabetes Mellitus, Type 2 | 2 | Completed | Nov 2007 | 487 |
| NCT00940329Healthy · Germany | 1 | Completed | Jul 2004 | 27 |
| NCT00746434Plaque Psoriasis | 2 | Withdrawn | Jun 2009 | 0 |
| NCT00746382Dermatitis | 2 | Withdrawn | Jun 2009 | 0 |
| NCT00430729Pulmonary Disease, Chronic Obstructive · Australia, Austria, Canada and more | 3 | Completed | 1,100 | |
| NCT00424268Pulmonary Disease, Chronic Obstructive · Austria, France, Germany and more | 3 | Completed | Jan 2008 | 743 |
| NCT00313209Pulmonary Disease, Chronic Obstructive · Austria, Belgium, Canada and more | 3 | Completed | Jul 2007 | 933 |
| NCT00297115Pulmonary Disease, Chronic Obstructive · United States, Canada, Germany and more | 3 | Completed | Apr 2008 | 1,568 |
| NCT00297102Pulmonary Disease, Chronic Obstructive · United States, Australia, Austria and more | 3 | Completed | Jul 2008 | 1,523 |
| NCT00246935Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | Jan 2007 | 150 |
| NCT00246922Asthma · Japan | 3 | Completed | Jan 1, 2007 | 150 |
| NCT00242320Pulmonary Disease, Chronic Obstructive · Hong Kong, Korea, Republic of, Malaysia and more | 3 | Completed | May 2007 | 551 |
| NCT00242307Asthma · Japan | 3 | Completed | Sep 1, 2006 | 450 |
| NCT00242294Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | Sep 2006 | 570 |
| NCT00163527Asthma · United States, Austria, Croatia and more | 3 | Completed | Nov 2005 | 2,054 |
| NCT00163475Asthma · Australia, Belgium, France and more | 3 | Completed | Aug 2005 | 511 |
| NCT00108823Pulmonary Disease, Chronic Obstructive · United States, Canada, France and more | 3 | Completed | 550 | |
| NCT00076089Pulmonary Disease, Chronic Obstructive · United States, Canada, France and more | 3 | Completed | Dec 2005 | 1,100 |
| NCT00076076Asthma · United States, Russian Federation, Ukraine | 3 | Completed | 822 | |
| NCT00073177Asthma · United States, Argentina, Colombia and more | 3 | Completed | 819 | |
| NCT00062582Pulmonary Disease, Chronic Obstructive · United States, Argentina, Canada and more | 3 | Completed | 1,000 |
How it is read
Names in the registry
- “Roflumilast”, 37 entries
- “Roflumilast Cream 0.15%”, 5 entries
- “Roflumilast Cream 0.3%”, 3 entries
- “ARQ-151 cream 0.05%”, 2 entries
- “Roflumilast Foam 0.3%”, 2 entries
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 21 studies
- Psoriasis, 13 studies
- Dermatitis, Atopic, 11 studies
- Asthma, 8 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.